Who
Joshua Schafer
Cco
Company insider
Files Form 4 as: Cco, Zevra Therapeutics; Director, Shuttle Pharmaceuticals Holdings.
In numbers
- Trades disclosed
- 28
- Buys
- 3
- Sells
- 3
- Bought
- $17K
- Sold
- $335K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 9 Jan 2023
- Last trade
- 3 Feb 2026
- Last filed
- 4 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Feb 2026filed 4 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $97K10,500 at $9.19 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $96K10,500 at $9.19 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —35,334 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,334 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,334 at $0.00 | filing |
| 31 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —35,334 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,333 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K3,375 at $8.83 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,333 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,333 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —11,333 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K3,375 at $8.83 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 29 Jan 2026filed 2 Feb 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 13 Feb 2025filed 14 Feb 2025 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $83K10,500 at $7.86 | filing |
| 31 Jan 2025filed 3 Feb 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —35,333 at $0.00 | filing |
| 31 Jan 2025filed 3 Feb 2025 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | —35,333 | filing |
| 30 Jan 2025filed 3 Feb 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —68,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.